Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    pipeline-prospector-insert-v1
    X

    Find Musculoskeletal Drugs in Phase III Clinical Development in UNITED STATES

    A collaboration with SCORR Marketing

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type

              Companies

              Catabasis Pharmaceuticals

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Pharma Nanotech & Nanomedicine

              Participation Not Confirmed

              Request a Meeting Now

              Catabasis Pharmaceuticals Announces Pricing of $23 Million Underwritten Public Offering

              Contact the Supplier

              Lead Product(s): Edasalonexent

              Therapeutic Area: Musculoskeletal

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Oppenheimer & Co.

              Deal Size: $23.0 million Upfront Cash: Undisclosed

              Deal Type: IPO January 30, 2020

              Details:

              Catabasis intends to use the net proceeds from the offering for clinical trial and other research and development activities; initial commercialization preparations; and for working capital.

              Ipsen, Inc

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Pharma Nanotech & Nanomedicine

              Participation Not Confirmed

              Request a Meeting Now

              Ipsen’s palovarotene clinical program in fibrodysplasia ossificans progressiva reaches prespecified interim analysis futility criteri...

              Contact the Supplier

              Lead Product(s): Palovarotene

              Therapeutic Area: Musculoskeletal

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 24, 2020

              Details:

              Ipsen to conduct further assessment of the complete data set and work with the regulatory authorities, based on encouraging therapeutic activity signals observed in preliminary post-hoc analyses.

              PharmaCompass__DigitalAd